Belite Bio Inc (BLTE)
54.69
0.59 (1.09%)
At close: Apr 09, 2025, 3:59 PM
54.88
0.35%
After-hours: Apr 09, 2025, 06:38 PM EDT
1.09% (1D)
| Bid | 50.89 |
| Market Cap | 1.74B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -36.14M |
| EPS (ttm) | -1.18 |
| PE Ratio (ttm) | -46.35 |
| Forward PE | -59.59 |
| Analyst | Buy |
| Ask | 61.5 |
| Volume | 70,545 |
| Avg. Volume (20D) | 42,240 |
| Open | 53.11 |
| Previous Close | 54.10 |
| Day's Range | 49.48 - 54.88 |
| 52-Week Range | 31.00 - 86.53 |
| Beta | -1.52 |
About BLTE
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that ...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 29, 2022
Employees 25
Stock Exchange NASDAQ
Ticker Symbol BLTE
Website https://belitebio.com
Analyst Forecast
According to 4 analyst ratings, the average rating for BLTE stock is "Buy." The 12-month stock price forecast is $100, which is an increase of 82.85% from the latest price.
Stock Forecasts2 months ago
+3.58%
Belite Bio shares are trading higher after Benchma...
Unlock content with
Pro Subscription
4 months ago
+5.34%
Belite Bio shares are trading higher after the company announced LBS-007 was granted FDA fast-track designation status for acute leukemia.
